+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tumor Targeting Peptides Market - Global Forecast 2026-2032- Product Image
Tumor Targeting Peptides Market - Global Forecast 2026-2032- Product Image
New

Tumor Targeting Peptides Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 190 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6126292
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Tumor targeting peptides are shaping the evolution of precision oncology, empowering organizations to achieve targeted therapy, advanced diagnostics, and more efficient drug delivery—all within globally connected life science markets. Their increasing clinical relevance is influencing not only the design of new products but also critical aspects of operational and supply chain planning.

Market Snapshot: Tumor Targeting Peptides Market

The Tumor Targeting Peptides Market is experiencing steady expansion, with the market value rising from USD 360.60 million in 2025 to USD 385.09 million in 2026 and projected to reach USD 570.50 million by 2032 at a CAGR of 6.77%. This growth is fueled by greater adoption within oncology therapeutics and diagnostics, driven by the unique capacity of peptides for targeted and modular interventions. Senior leaders are navigating a landscape where advances in peptide science rapidly intersect with operational considerations and shifting regulatory landscapes.

Scope & Segmentation

  • Product Formats: Includes ligand-only peptides, peptide-drug conjugates, peptide-radionuclide constructs, and peptide-enabled imaging agents, each addressing distinct needs in targeting and visualization.
  • Target Biology: Focus on overexpressed receptors, microenvironmental features, strategies that leverage integrins, and development of dual-function peptides to expand addressable tumor types.
  • Therapeutic vs. Diagnostic Applications: Encompasses payload delivery, imaging agents for assessing target engagement, and integrated theranostic solutions to streamline both diagnostic and treatment protocols.
  • End Users: Pharmaceutical and biotech companies targeting scalable production and differentiation, academic centers translating innovation, contract development and manufacturing organizations (CDMOs) focusing on manufacturability, and hospitals/diagnostic centers enabling deployment in clinical settings.
  • Regional Dynamics: Americas demonstrate robust biopharma activity and rapid clinic-to-market execution; Europe, Middle East, and Africa are recognized for regulatory maturity and translational capacity; Asia-Pacific is emerging as a center for manufacturing excellence, with government incentives accelerating next-generation therapeutic development.
  • Enabling Technologies: Advanced display and discovery platforms, data-driven sequence optimization, customizable linker engineering, and machine learning-assisted design directly support efficient peptide development and adoption.

Key Takeaways for Tumor Targeting Peptides

  • Peptide technologies have advanced from experimental molecules to critical tools, supporting selectivity and modularity in next-generation oncology therapeutics and diagnostics.
  • Improvements in peptide chemistry and stabilization have diversified potential applications, allowing use across radiopharmaceuticals, nanoparticles, and standalone agents.
  • The spectrum of actionable tumor targets is evolving, integrating microenvironmental factors—such as pH variations, protease activity, and tumor stroma—to help overcome biological complexity and heterogeneity.
  • Integration of computational design and optimization methods is lowering development risk, aligning peptide advancement with trends seen in antibody engineering and small molecule discovery.
  • Deployment of peptide-enabled imaging and companion diagnostics is strengthening the alignment between target validation and patient selection, enhancing the clinical impact of precision oncology strategies.
  • Strategic approaches now emphasize early-stage developability assessments, coordinated supply chain design, and operational collaboration from R&D to commercialization, which bolster standardization and responsiveness across the value chain.

Tariff Impact: Navigating United States Tariff Dynamics in 2025

Forthcoming United States tariffs introduce a more volatile procurement environment, particularly impacting the sourcing of protected amino acids, specialized reagents, and analytical supplies. These new dynamics result in longer lead times, increased inventory holdings, and a heightened focus on supplier diversification and renegotiation of contracts. Companies are being driven to rethink sourcing strategies by reinforcing platform standardization, supporting domestic supply chains, and minimizing exposure to global input price fluctuations. Resilient supply chain planning is essential for safeguarding production continuity and mitigating operational risk, especially for programs heavily reliant on global networks.

Methodology & Data Sources

Analysis incorporates direct interviews with scientists, clinical developers, CDMO partners, procurement professionals, and executive leaders, combined with systematic reviews of published and secondary market sources. Triangulation across these inputs validates key trends and benchmarks against operational best practices relevant to industry needs.

Why This Report Matters

  • Offers a structured framework for optimized R&D investment, supplier qualification, and strategic technology adoption across the tumor targeting peptides sector.
  • Converts complex scientific trends into actionable guidance for clinical, manufacturing, and commercialization teams, supporting better informed decision-making.
  • Equips organizations to reliably anticipate regulatory, operational, and regional market factors that influence the progression and scaling of tumor targeting peptide solutions.

Conclusion

The tumor targeting peptides market will remain a focal point of precision oncology. Prudent execution, resilient supply strategies, and data-driven development approaches will underpin clinical and commercial impact for organizations moving forward.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Tumor Targeting Peptides Market, by Peptide Type
8.1. Cyclic Peptides
8.2. Linear Peptides
8.3. Peptidomimetics
8.4. Self Assembling Peptides
9. Tumor Targeting Peptides Market, by Mechanism
9.1. Active Targeting
9.2. Passive Targeting
10. Tumor Targeting Peptides Market, by Development Stage
10.1. Approved
10.2. Phase I
10.3. Phase II
10.4. Phase III
10.5. Preclinical
11. Tumor Targeting Peptides Market, by Delivery Route
11.1. Intratumoral
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Tumor Targeting Peptides Market, by Application
12.1. Diagnostics
12.1.1. Biomarker Screening
12.1.2. Liquid Biopsy
12.2. Imaging
12.2.1. Magnetic Resonance Imaging
12.2.2. Optical Imaging
12.2.3. Positron Emission Tomography
12.3. Therapeutics
12.3.1. Immunotherapy
12.3.2. Radiotherapeutics
12.3.3. Targeted Drug Delivery
13. Tumor Targeting Peptides Market, by End User
13.1. Diagnostic Centers
13.2. Hospitals
13.3. Pharmaceutical Companies
13.4. Research Institutes
14. Tumor Targeting Peptides Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Tumor Targeting Peptides Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Tumor Targeting Peptides Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Tumor Targeting Peptides Market
18. China Tumor Targeting Peptides Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Amgen Inc.
19.6. AstraZeneca PLC
19.7. Bicycle Therapeutics PLC
19.8. Eli Lilly and Company
19.9. Ipsen S.A.
19.10. Medigene AG
19.11. Merck & Co., Inc.
19.12. Novartis AG
19.13. PeptiDream Inc.
19.14. Pfizer Inc.
19.15. Roche Holding AG
List of Figures
FIGURE 1. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL TUMOR TARGETING PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL TUMOR TARGETING PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDOMIMETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDOMIMETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDOMIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SELF ASSEMBLING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SELF ASSEMBLING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SELF ASSEMBLING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ACTIVE TARGETING, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ACTIVE TARGETING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ACTIVE TARGETING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PASSIVE TARGETING, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PASSIVE TARGETING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PASSIVE TARGETING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPROVED, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPROVED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPROVED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RADIOTHERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RADIOTHERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RADIOTHERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 144. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 145. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 147. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 148. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 150. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 151. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 164. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 165. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 166. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 167. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 168. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 169. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 170. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 171. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 185. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 186. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 187. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 188. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 189. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 190. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 191. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 192. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 194. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 195. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 196. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 197. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 198. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 199. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 200. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 201. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 202. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 215. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 216. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 217. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 218. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 219. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 220. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 221. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 222. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 223. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 225. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 226. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 227. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 228. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 229. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 230. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 231. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 232. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 235. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 236. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 237. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 238. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 239. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 240. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 241. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 242. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 255. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 256. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 257. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 258. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
TABLE 259. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 260. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 261. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 262. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 263. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Tumor Targeting Peptides market report include:
  • Amgen Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics PLC
  • Eli Lilly and Company
  • Ipsen S.A.
  • Medigene AG
  • Merck & Co., Inc.
  • Novartis AG
  • PeptiDream Inc.
  • Pfizer Inc.
  • Roche Holding AG

Table Information

Report AttributeDetails
No. of Pages190
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 385.09 Million
Forecasted Market Value ( USD ) by 2032 $ 570.5 Million
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Reports

Targeting Peptides Market - Global Forecast 2026-2032 - Product Image

Targeting Peptides Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032 - Product Image

Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Peptide Drug Conjugate Market, Drug Sales, Price, Dosage & Clinical Trials Insight 2030 - Product Image

Peptide Drug Conjugate Market, Drug Sales, Price, Dosage & Clinical Trials Insight 2030

  • Report
  • 120 Pages
  • Global
From
Antitumor Peptide Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Antitumor Peptide Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Peptide Drug Conjugates Market Report 2025 - Product Image

Peptide Drug Conjugates Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.